By Brazil Stock Guide – Goldman Sachs’ economic exposure to Oncoclínicas (B3: ONCO3) dropped to 9.08% following the company’s latest capital increase — a steep decline for an investor that once held close to 60% of the oncology group through derivative structures. The dilution stems entirely from the share issuance designed to reduce debt, lower leverage and strengthen liquidity at a time of rising regulatory pressure and cost inflation across Brazil’s healthcare sector.
Goldman’s current position is held through a cash-settled total return swap (TRS) referencing 102.9 million ONCO3 shares. Josephina II FIP, another Goldman-affiliated vehicle, saw its direct ownership shrink to 2.85% after not exercising preemptive rights, although its share count — 32.38 million — remains unchanged. The bank said it has no intention of altering control or influencing the company’s management.
The capital increase also reshapes the shareholder base as Oncoclínicas works to ring-fence its balance sheet following the collapse of Banco Master — one of its significant shareholders — which was liquidated by Brazil’s central bank and left ripple effects across credit structures and corporate exposures. The recapitalization comes as the company seeks to reduce uncertainties linked to Master’s failure and reinforce market confidence.
The updated ownership structure places Josephina III as the largest shareholder with 31.37%, followed by Banco Master with 14.96%, Latache with 14.33%, Bruno Ferrari with 8.58%, Josephina II with 4.9%, the management team with 1.01%, and treasury with 2.23%. The free float accounts for 22.62% of the 661.35 million outstanding shares.
Leave a Reply